Nitrous oxide and oxygen for use in treating ARDS caused by viral and bacterial infections, injuries, or other conditions that have resulted in acute, excess activation of the cytokine system in a patient in need thereof is provided. The treatment comprises administering nitrous oxide and oxygen to the patient by inhalation before, during, and/or after ARDS occurs. It is also applicable for treating, alleviating, and/or preventing an aftereffect of said conditions. A composition, duration, an interval, and a total amount of nitrous oxide and oxygen depend on each patient's individual situation and needs. Inhalation of nitrous oxide and oxygen can also stop the post ARDS symptoms that remain after an acute ARDS condition such as, but not limited to viral infections, bacterial infections, injuries, or any condition that results from any cytokine storm. Inhalation of nitrous oxide and oxygen can also treat local cytokine damages caused by said conditions.

Nitrous oxide and oxygen for use in treating ARDS caused by viral and bacterial infections, injuries, or other conditions that have resulted in acute, excess activation of the cytokine system in a patient in need thereof is provided. The treatment comprises administering nitrous oxide and oxygen to the patient by inhalation before, during, and/or after ARDS occurs. It is also applicable for treating, alleviating, and/or preventing an aftereffect of said conditions. A composition, duration, an interval, and a total amount of nitrous oxide and oxygen depend on each patient's individual situation and needs. Inhalation of nitrous oxide and oxygen can also stop the post ARDS symptoms that remain after an acute ARDS condition such as, but not limited to viral infections, bacterial infections, injuries, or any condition that results from any cytokine storm. Inhalation of nitrous oxide and oxygen can also treat local cytokine damages caused by said conditions.

The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as modulators of alpha 1 antitrypsin and treating diseases associated with alpha antitrypsin, particularly liver diseases.

This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.

Disclosed herein is a method of treating diseases and/or disorders associated with the dysregulated activation and recruitment of neutrophils. The method includes administering to a subject in need thereof an effective amount of 3,3′-dihydroxy-2′,6′-bis(p-hydroxybenzyl)-5-methoxybibenzyl (or bletinib), a salt, a solvate or an ester thereof.

Disclosed herein is a method of treating diseases and/or disorders associated with the dysregulated activation and recruitment of neutrophils. The method includes administering to a subject in need thereof an effective amount of 3,3′-dihydroxy-2′,6′-bis(p-hydroxybenzyl)-5-methoxybibenzyl (or bletinib), a salt, a solvate or an ester thereof.

Described is an antagonist of a mammalian P2X7R for use in the treatment of a hyperinflammatory syndrome in a mammalian patient, by primary lymph node targeted administration of the said P2X7R antagonist in the said patient to a concentration in the said targeted lymph nodes that is above the maximal tolerable plasma level of the said antagonist in the said mammal.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.

##STR00001##

Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary verso-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.